Stockreport

Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026

Kyverna Therapeutics, Inc.  (KYTX) 
PDF Late-breaking oral presentation to feature primary analysis from KYSA-8 registrational trial in stiff person syndrome (SPS) Oral presentation on updated KYSA-6 Phase 2 [Read more]